Alzheimer compounds development

Posted by Well carlota on December 3rd, 2019

Alzheimer's disease (AD) is a kind of chronic neurodegenerative disease, which is more common in the elderly. It brings a heavy burden to the family and society. The existing ad drugs can only improve the symptoms of ad in a short time, and can not effectively prevent and reverse the progression of AD. In view of the complex etiology of AD, a single compound acting on multiple ad related targets at the same time, i.e. "multi-target drugs" will be an important direction of Alzheimer structure-based drug design. Flavonoids widely exist in nature and have many pharmacological activities, which are worthy of further Alzheimer compounds development. According to the published literature, the flavonoids of multi-target anti Alzheimer's drugs were summarized in order to provide an important theoretical basis for the research and development of multi-target anti ad drugs.

Alzheimer's disease (AD), also known as Alzheimer's disease, is a chronic neurodegenerative disease that seriously threatens the elderly. The incidence increases with age. Its clinical manifestations are mainly memory dysfunction, accompanied by language, memory, cognition, reasoning, orientation and judgment, and gradually lose the ability of self-care. The main pathological features in the brain of AD patients are senile plaques formed by β - amyloid (a β) deposition, neurofibrillary tangles (NFT) formed by abnormal tau protein phosphorylation and loss of neurons. According to the global Alzheimer's report 2015 released by Alzheimer's International (ADI), more than 46 million people have dementia in the world, and the cost for dementia has reached US 8 billion. It is predicted that by 2050, there will be 131.5 million people suffering from ad in the world. At present, AChE inhibitors and N-methyl-D-aspartic acid approved by FDA for Ad.

NMDA receptor antagonists can only improve AD symptoms in a short period of time, and can not effectively prevent or reverse the course of disease. Therefore, there is an urgent need to develop new ad drugs with new characteristics in clinic The etiology of ad is complex, and its pathogenesis has not been fully elucidated.

With the deepening of research, researchers have put forward a variety of hypotheses, such as cholinergic hypothesis, β - amyloid (a β) hypothesis, tau protein phosphorylation hypothesis and gene mutation hypothesis. Based on the complex network pharmacology theory of ad disease, single target drugs regulating a node of disease network can not fundamentally inhibit the progress of AD. Aiming at inducing.

The so-called "one drug multiple targets" is expected to be a better strategy for the prevention and treatment of AD Flavonoids are widely distributed and are a kind of secondary metabolites produced by plants, vegetables and fruits. Flavonoids have become the focus of drug research at home and abroad because of their important therapeutic and preventive functions in anti-oxidation, cardiovascular protection, anti-tumor, anti neurodegenerative diseases and regulation of immunity Despite the potential efficacy of flavonoids in the treatment of AD, there are still low bioavailability and blood CSF barrier energy.

Because of the limitations of poor strength and lack of cholinesterase inhibitory activity, there are many research progress in the field of structural modification. In this paper, the research progress of flavonoids in multi-target anti Alzheimer's drugs was reviewed to provide theoretical reference for its further development.